Nov 19 Pfizer Inc said on Monday a
late-stage trial of a once-daily version of its drug Lyrica in
patients with fibromyalgia, a pain condition affecting more than
5 million Americans, met its main goal.
Patients taking once-daily Lyrica, also known as pregabalin,
went for a significantly longer period of time before feeling
pain compared with patients who took a placebo.
The study is the second of three late-stage trials testing a
controlled-release version of the drug, which is currently given
several times a day.
A trial of the controlled-release version of the drug in
patients with certain types of seizures did not meet its main
goal, Pfizer said.
The company is also studying the drug in patients with